<DOC>
	<DOCNO>NCT00046839</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Celecoxib may stop growth tumor cell stop blood flow tumor may make tumor cell sensitive radiation therapy . PURPOSE : Phase I/II trial study effectiveness combine celecoxib radiation therapy treat patient locally advance non-small cell lung cancer .</brief_summary>
	<brief_title>Celecoxib Radiation Therapy Treating Patients With Locally Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose recommend phase II dose concurrent celecoxib limited-field radiotherapy intermediate-prognosis patient locally advance non-small cell lung cancer . - Determine efficacy toxicity regimen patient . - Determine predictor mortality general population ( i.e. , comorbid condition , functional status , quality life , psychological status ) influence prognosis , toxicity , outcomes therapy patient treat regimen . - Correlate circulating level vascular endothelial growth factor ( VEGF ) , basic fibroblast growth factor ( bFGF ) , interleukin-8 ( IL8 ) survival patient treat regimen . - Correlate circulating level interleukin-1 ( IL1 ) , interleukin-6 ( IL6 ) , transform growth factor-beta ( TGFB ) pulmonary toxicity patient treated regimen . OUTLINE : This phase I dose-escalation study celecoxib follow phase II , multicenter study . - Phase I : Patients receive oral celecoxib twice daily . Beginning day 6 , patient undergo thoracic radiotherapy 5 day week 3-6.5 week . Patients continue receive celecoxib 2 year absence disease progression unacceptable toxicity . - Phase II : If few 3 first 6 patient experience dose-limiting toxicity , dose celecoxib escalate patient study , include first cohort . Quality life assess baseline 3 , 6 , 12 month start therapy . Patients follow every 3 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 6-12 patient accrued phase I portion study total 116 patient accrue phase II portion study within 25 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cyclooxygenase 2 Inhibitors</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer Inoperable stage IIB OR Unresectable stage IIIA IIIB No evidence hematogenous metastasis PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod 2 AND 5 % weight loss past 3 month OR Zubrod 01 AND less 5 % weight loss past 3 month refuse chemotherapy medically unable tolerate combine modality therapy Life expectancy Not specify Hematopoietic Not specify Hepatic Bilirubin great 2 time upper limit normal International Normalized Ratio ( INR ) great 3.0 take warfarin Renal Creatinine clearance least 50 mL/min Other No active gastrointestinal ulcer bleed within past 3 month No malignancy within past 3 year except nonmelanoma skin cancer No know hypersensitivity celecoxib No prior allergictype reaction sulfonamides No prior asthma , urticaria , allergictype reaction aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior neoadjuvant chemotherapy No concurrent chemotherapy Endocrine therapy No concurrent corticosteroid Radiotherapy No prior thoracic radiotherapy Surgery No prior complete subtotal tumor resection Other No concurrent NSAIDs , lithium , furosemide , angiotensinconverting enzyme inhibitor Concurrent aspirin ( 325 mg/day ) cardioprotection allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>